| 9.46 -11.8 (-55.5%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.23 |
1-year : | 31.95 |
| Resists | First : | 19.89 |
Second : | 27.36 |
| Pivot price | 13.57 |
|||
| Supports | First : | 7.82 |
Second : | 6.5 |
| MAs | MA(5) : | 18.52 |
MA(20) : | 12.79 |
| MA(100) : | 11.72 |
MA(250) : | 10.97 |
|
| MACD | MACD : | 1.5 |
Signal : | 1  |
| %K %D | K(14,3) : | 45 |
D(3) : | 64.6 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 27.36 | Low : | 7.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRXA ] has closed above bottom band by 29.3%. Bollinger Bands are 601.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.62 - 21.73 | 21.73 - 21.81 |
| Low: | 7.71 - 7.76 | 7.76 - 7.81 |
| Close: | 9.37 - 9.47 | 9.47 - 9.55 |
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers.
Tue, 16 Jun 2026
Why VERAXA Biotech AG (NASDAQ: VRXA) Is 'One to Watch' - Benzinga
Tue, 16 Jun 2026
Veraxa Biotech Holding (VRXA) Stock Analysis Report | Financials & Insights - Benzinga
Mon, 15 Jun 2026
symbol__ Stock Quote Price and Forecast - CNN
Fri, 12 Jun 2026
VERAXA Biotech (VRXA) Is 'One to Watch' - Yahoo Finance
Fri, 12 Jun 2026
Veraxa Biotech AG Financial Statements – NASDAQ:VRXA - TradingView
Thu, 11 Jun 2026
VERAXA Biotech (VRXA) Completes Business Combination, Begins Trading on Nasdaq - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 136 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -18.93 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|